Skip to content
PreclinicalResearch compoundLimited evidence

SKF‑38393

Selective dopamine D1 receptor partial agonist, a classic preclinical research tool.

DopaminergicResearch ChemicalDopaminergicMoodDopaminenoo.affects.focusnoo.affects.mood

Pharmacology

ClassDopaminergic · Mood
Primary targetDopamine D1 receptor partial agonist
Targets4 receptor targets
Half-lifeNot characterized in humans; noted for poor oral bioavailability and limited blood-brain barrier penetration
OnsetNo human data (research chemical)
EvidenceLimited evidence
Affected systemsDopaminenoo.affects.focusnoo.affects.mood

Contents

WHAT IS SKF-38393?

Detailed overview

SKF-38393 is a 1-phenyl-benzazepine, a selective partial agonist of dopamine D1-like (D1/D5) receptors and one of the oldest and most widely used research tools in neuropharmacology for mapping the role of D1 receptors. Receptor activation stimulates adenylyl cyclase through the Gs protein, raising intracellular cAMP, and manifests behaviorally as effects on movement, arousal, sleep, and feeding via striatal and prefrontal circuits. In rodents it elicits characteristic self-grooming behavior, reduces REM sleep, and decreases food intake. Only the (R)-enantiomer is behaviorally active. It has no human clinical or therapeutic use: the compound is uncharacterized in humans and exists solely as an experimental research chemical.

Mechanism

D1/D5 partial agonist (raises cAMP)

Evidence

Preclinical only (no human data)

Legal status

Unapproved research chemical

Receptor profile

  • Dopamine D1 receptorStrong
  • Dopamine D5 receptorModerate
  • Adenylyl cyclase / cAMP pathwayModerate
  • Striatal motor circuitsModerate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • No human safety data: the compound is only a preclinical (rodent and cellular) pharmacological tool and has never been tested therapeutically in humans
  • Increased self-grooming behavior in animals, a hallmark of D1 agonism
  • Reduced REM sleep and altered sleep architecture in animal studies
  • Reduced food intake (appetite-suppressing effect) in rodents
  • Cardiovascular effects (changes in blood pressure and heart rate) in animal models
  • Unknown long-term safety and a completely uncharacterized toxicity profile in humans

Contraindications · 4

  • Pregnancy and breastfeeding: safety not established, avoid
  • Cardiovascular disease: the dopaminergic effect may theoretically alter blood pressure and heart rate
  • Psychotic disorders: dopamine receptor stimulation may theoretically worsen symptoms
  • Not an approved medicine; strictly a laboratory research chemical, not intended for human consumption

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Selective dopamine D1 receptor partial agonist, a classic preclinical research tool.

Telegram

Have a question about SKF‑38393?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeDopaminergic
FormulaC16H17NO2
UpdatedJuly 10, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: July 10, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.